Aneuploidy leads to genome instability, which eventually produces cell cycle-arrested cells with complex karyotypes. This paper provides a simple and convenient method to isolate aneuploid cells with complex karyotypes that cease to divide.
Chromosome mis-segregation leads to aneuploidy, a condition in which cells harbor an imbalanced chromosome number. Several lines of evidence strongly indicate that aneuploidy triggers genome instability, ultimately generating cells with complex karyotypes that arrest their proliferation. Isolation and characterization of cells harboring complex karyotypes are crucial to study the impact of an imbalanced chromosome number on cell physiology. To date, no methods have been established to reliably isolate such aneuploid cells. This paper provides a protocol for the enrichment and analysis of aneuploid cells with complex karyotypes utilizing standard, inexpensive tissue culture techniques. This protocol can be used to analyze several features of aneuploid cells with complex karyotypes including their induced senescence-associated secretory phenotype, pro-inflammatory properties, and ability to interact with immune cells. Because cancer cells often harbor imbalances in chromosome number, it is crucial to decipher how aneuploidy impacts cell physiology in normal cells, with the ultimate goal of uncovering both its pro- and anti-tumorigenic effects.
Errors in the process of chromosome segregation lead to aneuploidy, a condition characterized by a chromosome number that is not a multiple of the haploid complement1,2,3,4. Aneuploid karyotypes trigger replication stress that generates further genomic instability5,6,7,8,9,10, increases karyotype complexity, and ultimately leads to cell cycle arrest of a subpopulation of cells10. The purpose of the method presented here is to generate and separate such a subpopulation from cycling cells. By employing inexpensive tissue culture techniques, this protocol facilitates the isolation and characterization of cell cycle-arrested aneuploid cells with complex karyotypes. These cells are referred to as ArCK (Arrested with Complex Karyotype) cells and their euploid cycling counterparts as controls.
This protocol is the first one to be established for this purpose and allows for the isolation and further study of ArCK lines including, but not limited to, their induced senescence and the senescence-associated secretory phenotype (SASP), their pro-inflammatory features, and their ability to engage with immune cells. The method presented here has been developed in untransformed, immortalized human cells but has not yet been tested in cancer lines. Some transformed cells may be insensitive to cell cycle arrest due to suppression of one or multiple pathways; therefore, further validation should be performed in other cell lines.
Culture condition
RPE-1 hTERT cell line was cultured in Dulbecco's Modified Eagle Medium (Table of Materials) supplemented with 10% Fetal Bovine Serum, 2 mM L-glutamine, and 100 U/ml penicillin/streptomycin. Cells were incubated at 37 °C with 5% CO2 in a humidified environment. The protocol described below has been developed by using 10-cm dishes and all technical details reported refer to those dishes. If using different dishes, scale up or down accordingly.
1. Synchronization of RPE-1 cells
2. Generation of Aneuploid Cells by Interference with the Activity of the Mitotic Kinase Mps1
3. Removal of Aneuploid Cycling Cells and Enrichment of ArCK Population
Figure 1: Overall schematic of the method used to generate and isolate aneuploid cells with complex karyotype (ArCK) and representative images. (A) Schematic of ArCK cells generation and isolation protocol. (B) Representative images of RPE-1 hTERT cells at each stage of the treatment. The last panel (outlined in red) represents the isolated ArCK cells. Scale bar 100 µm. Please click here to view a larger version of this figure.
4. Characterization of ArCK Population
This method utilizes an in vitro tissue culture system to isolate aneuploid cells with complex karyotypes that arrest their proliferation. This population is referred to as ArCK (Arrested with Complex Karyotypes) cells. Figure 1A shows the scheme of the experiment. Wild-type cycling RPE-1 hTERT cells are synchronized at the G1/S border with thymidine and treated with a Mps1 inhibitor to induce chromosome mis-segregation. The spindle poison nocodazole is added to the cells 72 h after induction of chromosome mis-segregation. 12 h after nocodazole treatment, the aneuploid cells that are still able to proliferate enter mitosis and are trapped in this cell cycle stage due to interference with microtubule polymerization. These trapped cells are then easily removed by gentle shake-off. The shake-off process is repeated 3 – 5 times to ensure complete removal of cycling cells. Figure 1B shows the representative images of RPE-1 cells at each stage of the treatment.
ArCK cells display increased levels of cell cycle inhibitors, such as p53, p21, and p16 compared to euploid and aneuploid cycling cells, as shown in Figure 2A. Additionally, Figure 2B shows positive β-galactosidase staining in ArCK cells in comparison to euploid control cells, a well-established marker for cellular senescence.
Figure 2: Representative results utilizing ArCK cells. (A) Western blot assessing cell cycle inhibitor levels in euploid, aneuploid cycling, and ArCK cells. The levels of p53, p21, and p16 were determined by western blot analysis. Actin served as a loading control. (B) β-galactosidase staining assessing the level of senescence in ArCK cells. Senescence-associated β-galactosidase (β-Gal) activity was determined in euploid cells and ArCK cells. Scale bar 100 µm. Please click here to view a larger version of this figure.
This cell cycle arrest is a prominent feature of aneuploid cells with complex karyotypes, as shown by representative karyotype analysis from single-cell sequencing in Figure 3, in which ArCK cells display multiple, random chromosome gains and losses. This finding is in full agreement with previous reports10.
Figure 3: Representative single-cell sequencing of ArCK cells. Segmentation plots showing the karyotype of six representative ArCK cells. Segmentation plots show the copy number of all chromosomes from 1 to X relative to a euploid reference on a log2 scale (wild type RPE-1 is a diploid cell line of female origin). Chromosome gains are highlighted in red, chromosome losses in green. Please click here to view a larger version of this figure.
This novel method to generate and enrich for arrested cells with complex karyotypes (ArCK) allows for the study of cells that have multiple chromosome gains or losses and cease to divide. The method setup has been designed to facilitate the isolation of ArCK cells in a quick and reliable way.
The most critical step in this assay is rigorously controlling the timeline of drug treatment and, most importantly, the removal of aneuploid cycling cells. For optimal results, the timing of nocodazole treatment and shake-off is of particular importance to ensure that cycling cells are removed from the plate while they are still rounded and mitotic, preventing the possibility of mitotic cell death or slippage into G1, potentially creating a tetraploid population. It is not recommended that the timing of shake-off deviates more than two hours from the recommended 12-h nocodazole incubation.
Future studies on ArCK cells have the potential to facilitate a deeper understanding of how complex karyotypes affect cell physiology. In particular, a recent study demonstrated that cells of the immune system are able to interact with and trigger immune clearance of ArCK cells10. The method described here provides an excellent starting point for further characterization of ArCK cells, including the clarification of the molecular mechanisms underlying immune clearance in untransformed cells and the study of how oncogenic transformation may bypass this surveillance mechanism, a crucial question in the field14,15.
The authors have nothing to disclose.
This work was supported in part by the Koch Institute Support (core) Grant P30-CA 14051 from the National Cancer Institute, by the National Institutes of Health Grant (CA206157-22 and GM118066) and Curt Marble Cancer Research Fund to Angelika Amon. Angelika Amon is also an investigator of the Howard Hughes Medical Institute and the Glenn Foundation for Biomedical Research. S. S. was supported by the American Italian Cancer Foundation (AICF), by a Fellowship in Cancer Research from Marie Curie Actions and the Italian Association for Cancer Research (AIRC), and by a KI Quinquennial Cancer Research Fellowship. E.M. was supported by a fellowship from the Howard Hughes Medical Institute.
DMEM (Dulbecco’s Modified Eagle Medium) | Thermofisher | 11995-073 | |
Thymidine | Sigma Aldrich | T1859 | |
Reversine | Cayman Chemical Company | 10004412 | |
Nocodazole | Sigma Aldrich | M1410 | |
Anti-p53 antibody | Santa Cruz | sc-126 | |
Anti-p21 antibody | Santa Cruz | sc-6246 | |
Anti-p16 antibody | BD | 554079 | |
Senescence b-Galactosidase Staining Kit | Cell Signaling Technology | 9860 | |
Proteome Profiler Human Cytokine Array Kit | R&D Systems | ARY005B |